公开(公告)号：US20200246314A1

公开(公告)日：2020-08-06

申请号：US16853121

申请日：2020-04-20

申请人： KOWA COMPANY, LTD.

发明人： Yuta Inokuchi ,  Toshiaki Takizawa

IPC分类号： A61K31/423 ,  A61K31/455

摘要： This invention provides a combination-drug composition and a combination use of pharmaceuticals for preventing and/or treating dyslipidemic conditions such as hyper-LDL cholesterolemia in mammals, including humans. This invention pertains to a drug composition for preventing and/or treating dyslipidemia and the like, the drug composition including the following: (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy] butyric acid, a salt thereof, or a solvate of either; and nicotinic acid and nicotinic-acid amide, collectively referred to as niacin, an ester derivative thereof, a salt thereof, or a solvate of any of these.

公开(公告)号：US10701258B2

公开(公告)日：2020-06-30

申请号：US16474620

申请日：2018-01-30

申请人： KOWA COMPANY, LTD.

发明人： Tomohisa Azegami

IPC分类号： H04N5/232 ,  H04Q9/00 ,  H04W84/12 ,  H04L5/00

摘要： [Problem] To enable imaging to be performed with appropriate timing.[Solution] In a camera manipulation device 1 according to the present invention, a trigger signal T12 is issued and imaging is begun when a prescribed command is transmitted from a control circuit side to an imaging unit side (see S12). Because the issuance of such trigger signal T12 is not accepted before a character reception start command is issued, it is possible to perform imaging with appropriate timing.

公开(公告)号：US20200151909A1

公开(公告)日：2020-05-14

申请号：US16609669

申请日：2018-04-27

申请人： KOWA COMPANY, LTD.

发明人： Katsumi YABUSAKI

IPC分类号： G06T7/90

摘要： Provided are an analysis evaluation method and device, and a computer program for the state of a subject surface in a still image. The method includes: a step of acquiring color information of each pixel in a predetermined region in a still image, a step of calculating a numerical value indicating a diversity of color from the acquired color information, a step of calculating an average value of the color information, and a step of calculating a coefficient of variation on the basis of the calculated numerical value indicating the diversity of color and the calculated average value of the color information. Herein, the coefficient of variation is used as an index for evaluating the surface state of an object.

公开(公告)号：US20200022960A1

公开(公告)日：2020-01-23

申请号：US16477416

申请日：2018-01-11

申请人： Kowa Company, Ltd.

发明人： Yusuke Sasaki ,  Masato Asahiyama ,  Toshiya Tanaka

IPC分类号： A61K31/423 ,  A61P1/16

摘要： The present invention addresses the problem of providing a medicinal composition and a drug combination by which nonalcoholic fatty liver disease and nonalcoholic steatohepatitis can be prevented and/or treated. The present invention provides a combination of a peroxisome proliferator-activated receptor (PPAR) α agonist with a sodium glucose cotransporter 2 (SGLT2) inhibitor, which is to be used for preventing and/or treating nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

公开(公告)号：USD863060S1

公开(公告)日：2019-10-15

申请号：US29596298

申请日：2017-03-07

申请人： KOWA COMPANY, LTD.

设计人： Haruyasu Abe ,  Masato Seki

公开(公告)号：US20190282139A1

公开(公告)日：2019-09-19

申请号：US16345107

申请日：2017-11-02

申请人： Kowa Company, Ltd.

发明人： Takaharu ASANO ,  Katsumi YABUSAKI

IPC分类号： A61B5/145 ,  A61B5/1455

摘要： Provided are an in-blood component measurement method, an in-blood component measurement device, and an in-blood component measurement program, enabling more accurate measurement of a proportion of glycohemoglobin in the total hemoglobin concentration in blood. The in-blood component measurement method is designed to have a constitution including the steps of irradiating, with near-infrared light, blood that is a target to be measured for a proportion of glycohemoglobin in the total hemoglobin concentration in blood, receiving transmitted light of the near-infrared light passing through the blood, measuring an absorption spectrum of the blood on the basis of the transmitted light received, and calculating the proportion for the blood that is the target of measurement by comparing absorbance at a first wavelength range including 1450 nm in the measured absorption spectrum to absorbance at the first wavelength range in the absorption spectrum of blood in which the proportion is already known.

公开(公告)号：US20190167645A1

公开(公告)日：2019-06-06

申请号：US16272050

申请日：2019-02-11

申请人： KOWA COMPANY, LTD.

发明人： Toshiaki Takizawa ,  Yasunobu Yoshinaka

IPC分类号： A61K31/423 ,  A61K45/06 ,  A61K31/397

摘要： The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor.

公开(公告)号：US20190117059A1

公开(公告)日：2019-04-25

申请号：US16210038

申请日：2018-12-05

申请人： KOWA COMPANY, LTD.

发明人： Satoshi SHIMADA ,  Takuya HARA

IPC分类号： A61B3/024 ,  A61B3/00

摘要： In a perimetry to be conducted, designating an inspection region through a region designator, a perimeter is configured to set a required time of the perimetry (upper limit time) through an upper limit condition setter and to determine total number or positions of stimulus presentation spots based upon the upper limit time. In such a configuration, an examinee knows the time to finish the inspection, and is able to highly keep his (her) concentration in comparison with a case where the required time is not known, thereby improving precision of the inspection.

公开(公告)号：US20180289719A1

公开(公告)日：2018-10-11

申请号：US16005136

申请日：2018-06-11

申请人： KOWA COMPANY, LTD.

发明人： Isamu SAWAI

IPC分类号： A61K31/551 ,  A61K9/08 ,  A61K31/5575 ,  A61P27/06 ,  C08L23/12 ,  A61K45/06 ,  A61K47/14 ,  A61K9/00 ,  A61K31/18 ,  A61K31/502

摘要： A technique is provided for reducing the discoloration of an aqueous composition containing a halogenated isoquinoline derivative during high-temperature preservation. An aqueous composition comprising a compound represented by Formula (1): wherein X represents a halogen atom, or a salt thereof, or a solvate of the compound or the salt thereof, and a prostaglandin.

公开(公告)号：US09968592B2

公开(公告)日：2018-05-15

申请号：US15513277

申请日：2015-09-28

申请人： KOWA COMPANY, LTD.

发明人： Yuta Inokuchi ,  Haruki Shibata ,  Toshiaki Takizawa

IPC分类号： A61K31/423 ,  A61K31/4152 ,  A61K45/06 ,  A61K45/00

CPC分类号： A61K31/423 ,  A61K31/4152 ,  A61K31/421 ,  A61K31/505 ,  A61K45/00 ,  A61K45/06 ,  A61K2300/00

摘要： This invention provides a combination-drug composition and a combination use of pharmaceuticals for preventing and/or treating dyslipidemic conditions such as hyper-LDL cholesterolemia in mammals, including humans.This invention pertains to a drug composition for preventing and/or treating dyslipidemia and the like, the drug composition including the following: (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy] butyric acid, a salt thereof, or a solvate of either; and (S)-trans-{4-[({2-[({1-[3,5-bis(trifluoromethyl)phenyl]ethyl}{5-[2-(methyl sulfonyl)ethoxy]pyrimidin-2-yl}amino)methyl]-4-(trifluoromethyl)phenyl}(ethyl)amino)methyl]cyclohexyl} acetic acid, a salt thereof, or a solvate of either.